A Tufts CSDD survey run in 2022 and published in 2024 found that 76% of protocols had at least one amendment, up from 57% in an earlier study. The earlier analysis put the median direct cost of a substantial amendment at $141,000 for a Phase II protocol and $535,000 for Phase III (Tech Funding News, citing Tufts CSDD; Getz et al., PubMed).
Most of that cost reaches the sponsor as change orders, from the CRO, central lab, imaging vendor or sites. Change orders matter to vendors too: a Clinical Trials Arena report noted that for CROs, change orders can generate up to 100% additional revenue, and advised sponsors to anticipate their impact and set aside a share of the trial budget for them (Clinical Trials Arena).
The usual problem is timing. A change order arrives after the amendment is decided, priced by the vendor, and the sponsor has little independent view of whether the amount is right. Forecasting the amendment before agreeing the change order changes that.
|
Question |
Why it matters |
|---|---|
|
Is the change out of the original scope? |
Some work is already covered by the contract |
|
Which visits and procedures does the amendment change? |
Cost follows the schedule of assessments |
|
Which regions and sites are affected? |
Not every amendment applies everywhere |
|
How many participants are still to be enrolled or treated? |
Remaining volume drives remaining cost |
|
How does the change compare with the current forecast? |
Shows whether the budget can absorb it |
|
What has been spent so far against the original scope? |
Separates overruns from genuine new scope |
An amendment that adds an MRI at two visits, extends enrolment in one region, or adds a safety lab changes specific visits and procedures. Costing those changes against the current budget shows what the change order should roughly be before the vendor's quote arrives.
An amendment may affect only some countries, for example where a regulator has asked for an extra assessment, or only sites still enrolling. Forecasting by region and site keeps the change order to the sites that are affected.
The cost of an amendment depends on how many participants and visits are still to come. A study that is 70% enrolled has less remaining exposure than one that has just started. The forecast should use actual progress.
Some amendments can be absorbed within the existing budget or contingency. Others cannot. Seeing the forecast with and without the amendment shows which, and by how much.
Once approved, the change order should update the budget and forecast, so the next amendment is measured against the right baseline. Tracking spend against each change order shows whether it is running to plan.
Cloudbyz Clinical Trial Financial Management (CTFM), built natively on Salesforce alongside Cloudbyz CTMS and EDC, includes a forecasting module that lets study teams model protocol amendment scenarios against the current budget and actual study progress. It shows whether a change order is likely to be needed, how much it would be, and which regions and sites it affects, and then tracks how spend is running against it. Because site budgets, visit plans and enrolment share one platform, the forecast uses the study as it is, not as it was planned.
Book a demo or visit cloudbyz.com.